Skip to main content
. 2016 Oct 19;5(12):3386–3393. doi: 10.1002/cam4.919

Table 3.

Resolution of macrocytosis in patients with follow‐up

Sunitinib (n = 27)a Sorafenib (n = 4)
Macrocytosis resolved while on therapy with tyrosine kinase inhibitor 37% 75%
Macrocytosis resolved during follow‐up 100% 100%
Median time to resolution after stopping therapy 1 m 0 m
a

Missing follow‐up information for 4/31 patient patients that explains n = 27.